Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Cytokinetics (CYTK)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Day One Biopharmaceuticals (DAWN – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Day One Biopharmaceuticals (DAWN)
In a report released today, Ami Fadia from Needham maintained a Buy rating on Day One Biopharmaceuticals, with a price target of $17.00. The company’s shares closed last Tuesday at $12.02.
According to TipRanks.com, Fadia is a 5-star analyst with an average return of
Day One Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $22.00, implying an 86.8% upside from current levels. In a report issued on February 23, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Cytokinetics (CYTK)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Cytokinetics, with a price target of $85.00. The company’s shares closed last Tuesday at $70.10, close to its 52-week high of $75.71.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $92.79, representing a 35.6% upside. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.
